Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of a meta-analysis in which the benefit of the combination of a mucoprotectant (xyloglucan or an equivalent substance), hibiscus and propolis in the management of uncomplicated urinary tract infections has been evaluated. Among different available publications, three of them were integrated into the final analysis leading the authors to interesting conclusions: “In the era of antibiotic resistance, an antibiotic-sparing approach presents an interesting alternative treatment of uncomplicated cystitis in women…“ and “A medical device containing xyloglucan, hibiscus and propolis is superior to comparator regimens in terms of clinical effectiveness in adult women with microbiologically confirmed or clinical suspicion of uncomplicated cystitis and is associated with a high patient compliance”, thus reinforcing the usefulness of Utipro® Plus/Utipro® Plus AF in acute and recurrent uncomplicated UTIs.
Utipro® Plus and Utipro® Plus AF are medical devices intended for the control and prevention of uncomplicated urinary tract infections and comply with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (Utipro® Plus CE 0373, Noventure SL - Utipro® Plus AF CE 0476, Noventure SL)
Link to open access paper: https://doi.org/10.3390/antibiotics11010014
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.